Drug intelligence / Profile preview

TSP-102

Development stage: Unknown
Lead developer: Tensegrity Pharma
Modality: Small Molecules

Overview

TSP-102 is a small molecule therapeutic candidate being developed by Tensegrity Pharma for various non-oncology indications. It is described as the same molecular entity as TSP-101, which is being developed for cancer cachexia. The drug's mechanism of action involves blocking the signaling of specific factors that are over-expressed in disease states and suppressing inflammatory responses. While the exact molecular targets and the specific non-oncology diseases under investigation have not been publicly disclosed, the drug is currently in Phase 1 clinical development.

Targets

TNFRSF12A (Tumor necrosis factor-like weak inducer of apoptosis receptor)

Beyond the preview

Go deeper on TSP-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSP-102.

Explore the full profile